Temasek Life Sciences Laboratory Limited
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
1
Ending by 2030
Dec 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Dec 4 to 18, 2026 · next Dec 4
- 1 fee due Feb 25, 2027The maintenance fee for Monoclonal antibodies specific to hemagglutinin from influenza virus H5-subtype and uses thereof (US 9,115,188) comes due Feb 25, 2027. Unpaid by Aug 25, 2027, it lapses early.
- 2 fees due Jul 2 to 12, 2027 · next Jul 2
Recent changes
- 3 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,115,188 | Monoclonal antibodies specific to hemagglutinin from influenza virus H5-subtype and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 9,555,093 | Universal vaccine against H5N1 lineages In force · From the USPTO record | In force | From the USPTO record | |
| US 9,233,152 | Monoclonal antibodies targeting neutralizing epitopes on H5 influenza virus of clade 2.3 In force · From the USPTO record | In force | From the USPTO record | |
| US 10,202,617 | Expression cassette for efficient surface display of antigenic proteins In force · From the USPTO record | In force | From the USPTO record | |
| US 9,574,205 | Microsomal ω6 oleate desaturases In force · From the USPTO record | In force | From the USPTO record | |
| US 9,580,363 | Nitrogen-fixing bacterial inoculant for improvement of crop productivity and reduction of nitrous oxide emission In force · From the USPTO record | In force | From the USPTO record | |
| US 9,637,537 | Monoclonal antibodies targeting neutralizing epitopes on H7 influenza viruses In force · From the USPTO record | In force | From the USPTO record | |
| US 10,106,802 | Polynucleotide sequences from rhodosporidium and rhodotorula and use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,100,321 | Methods for increasing cotton fiber length In force · From the USPTO record | In force | From the USPTO record | |
| US 9,694,067 | Monovalent H5 vaccine In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 25: 3 patents in force now held by others · 46 lapsed for an unpaid fee · 8 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 1 abandoned · 7 no status recorded